期刊
UROLOGIA INTERNATIONALIS
卷 84, 期 4, 页码 445-451出版社
KARGER
DOI: 10.1159/000304510
关键词
Prostate cancer; TRAIL; Androgen ablation therapy; Hormone-refractory prostate cancer
资金
- Akdeniz University
Background: It is not known whether androgen ablation therapy (AAT) influences TRAIL death ligand and its receptors expression of prostate cancer (PCa) cells. Aim: To investigate whether hormonal therapy alters the expression of TRAIL death ligand and TRAIL receptors in patients with advanced PCa. Patients and Methods: 26 untreated and 20 AAT-treated advanced PCa patients were included in the study. The patients who received AAT were divided into two groups based on hormone sensitivity status. TRAIL ligand and receptor expression were determined by a conventional immunohistochemistry method. Results: TRAIL death ligand and TRAIL-R2 death receptor were upregulated in PCa patients who received AAT. Hormone-refractory PCa patients exhibited lower levels of TRAIL death receptor (TRAIL-R1 and TRAIL-R2) expression compared to hormone-sensitive PCa patients. Conclusions: AAT alters TRAIL death ligand and its receptors expression in patients with PCa. Copyright (C) 2010 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据